-- 汤森路透(TRI.TO)周二表示,公司第一季度调整后盈利和营收均超出预期。 剔除大部分一次性项目后,调整后盈利从去年同期的5.06亿美元(合每股1.12美元)增至5.47亿美元(合每股1.23美元)。据FactSet数据显示,该业绩高于分析师普遍预期的每股1.21美元。 总营收增长10%至20.9亿美元,高于分析师预期的16亿美元。公司表示,营收增长主要得益于经常性收入(占总营收的77%)增长10%和交易收入增长15%,但部分被全球印刷业务4%的下滑所抵消。 汤森路透预计第二季度有机营收增长率将在7%至8%之间,调整后EBITDA利润率将达到38%。 该公司维持了2026年全年业绩展望(2月5日公布),除净利息支出外,所有指标均保持不变。净利息支出预计将在1.8亿美元至1.9亿美元之间,而该公司2月份的展望为1.5亿美元至1.6亿美元。此次上调反映了12亿美元的股票回购计划、资本返还和股份合并交易。 该公司在2月份宣布将股息提高10%,至每股年化2.62美元。该公司将于6月10日向5月20日登记在册的股东支付更高的季度股息,每股0.655美元。 “我们为2026年开了个好头,”首席执行官史蒂夫·哈斯克表示,“我们积极的发展势头反映了专业人士在关键时刻对汤森路透的信任。”哈斯克表示,专业人士在法律、税务、审计和合规领域都选择了汤森路透的人工智能产品。 周一,汤森路透的股票在多伦多证券交易所收盘上涨 0.31 美元,至 130.50 美元。
Related Articles
Citigroup Adjusts Price Target on Marathon Petroleum to $257 From $243, Maintains Neutral Rating
Marathon Petroleum (MPC) has an average rating of overweight and mean price target of $253.25, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $256.58, Change: $+4.04, Percent Change: +1.60%
Research Alert: Peg Reports Strong Q1 Beat; On Track For $4.2b Capex And 7% Eps Growth In 2026
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:PEG reported Q1 2026 adjusted EPS of $1.55 vs. $1.43 (+8.4% Y/Y, +8.5% vs. consensus), supported by higher PSE&G margins from regulated infrastructure investments and customer growth, partially offset by higher depreciation and interest expense. PSEG Power earnings increased due to higher realized power prices and lower O&M costs, offset by lower generation volumes. We see the company as on target for $4.2B full-year 2026 capex guidance after deploying ~$0.8B in Q1, while PEG maintained long-term targets including $24B-$28B total capex for 2026-2030 and a 6%-7.5% rate base CAGR. Management reaffirmed its 2026 EPS guidance of $4.28-$4.40, representing ~7% growth at the midpoint. Both residential electric and gas customers increased ~1% on a trailing-12-month basis, which we think reflects continued execution of the regulated investment program. Annualized dividends were increased ~6% to $2.68 for 2026. We view this as a competitive growth rate amongst Multi-Utility peers.
Merck Completes Terns Pharmaceuticals Acquisition
Merck (MRK) said Tuesday it has completed the acquisition of Terns Pharmaceuticals after a cash tender offer at $53 per share.Terns' stock will no longer be listed on Nasdaq, it said.The deal will result in a charge to research and development expense of about $2.35 per share, included in Q2 and full year 2026 GAAP and non-GAAP results, Merck said.GAAP and non-GAAP EPS are also expected to take a hit of about $0.12 a share in 2026 on costs associated with advancing TERN-701 and costs of financing, it added.Price: $113.21, Change: $+0.10, Percent Change: +0.09%